PMID- 28174489
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1000-9604 (Print)
IS  - 1993-0631 (Electronic)
IS  - 1000-9604 (Linking)
VI  - 28
IP  - 6
DP  - 2016 Dec
TI  - ALK gene expression status in pleural effusion predicts tumor responsiveness to 
      crizotinib in Chinese patients with lung adenocarcinoma.
PG  - 606-616
LID - 10.21147/j.issn.1000-9604.2016.06.07 [doi]
AB  - OBJECTIVE: The relationship between anaplastic lymphoma kinase (ALK) expression 
      in malignant pleural effusion (MPE) samples detected only by Ventana 
      immunohistochemistry (IHC) ALK (D5F3) and the efficacy of ALK-tyrosine kinase 
      inhibitor therapy is uncertain. METHODS: Ventana anti-ALK (D5F3) rabbit 
      monoclonal primary antibody testing was performed on 313 cell blocks of MPE 
      samples from Chinese patients with advanced lung adenocarcinoma, and fluorescence 
      in situ hybridization (FISH) was used to verify the ALK gene status in Ventana 
      IHC ALK (D5F3)-positive samples. The follow-up clinical data on patients who 
      received crizotinib treatment were recorded. RESULTS: Of the 313 MPE samples, 27 
      (8.6%) were confirmed as ALK expression-positive, and the Ventana IHC ALK 
      (D5F3)-positive rate was 17.3% (27/156) in wild-type epidermal growth factor 
      receptor (EGFR) MPE samples. Twenty-three of the 27 IHC ALK (D5F3)-positive 
      samples were positive by FISH. Of the 11 Ventana IHC ALK (D5F3)-positive patients 
      who received crizotinib therapy, 2 patients had complete response (CR), 5 had 
      partial response (PR) and 3 had stable disease (SD). CONCLUSIONS: The ALK gene 
      expression status detected by the Ventana IHC ALK (D5F3) platform in MPE samples 
      may predict tumor responsiveness to crizotinib in Chinese patients with advanced 
      lung adenocarcinoma.
FAU - Wang, Zheng
AU  - Wang Z
AD  - Department of Pathology, Beijing Hospital, National Center of Gerontology, 
      Beijing 100730, China.
FAU - Wu, Xiaonan
AU  - Wu X
AD  - Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, 
      Beijing 100730, China.
FAU - Han, Xiaohong
AU  - Han X
AD  - Department of Medical Oncology, National Cancer Center/Cancer Institute & 
      Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 
      Beijing 100021, China.
FAU - Cheng, Gang
AU  - Cheng G
AD  - Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, 
      Beijing 100730, China.
FAU - Mu, Xinlin
AU  - Mu X
AD  - Department of Respiratory and Critical Care Medicine, Peking University People's 
      Hospital, Beijing 100044, China.
FAU - Zhang, Yuhui
AU  - Zhang Y
AD  - Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital 
      Medical University, Beijing 100020, China.
FAU - Cui, Di
AU  - Cui D
AD  - Department of Pathology, Beijing Hospital, National Center of Gerontology, 
      Beijing 100730, China.
FAU - Liu, Chang
AU  - Liu C
AD  - Department of Medical Oncology, PLA Army General Hospital, Beijing 100700, China.
FAU - Liu, Dongge
AU  - Liu D
AD  - Department of Pathology, Beijing Hospital, National Center of Gerontology, 
      Beijing 100730, China.
FAU - Shi, Yuankai
AU  - Shi Y
AD  - Department of Medical Oncology, National Cancer Center/Cancer Institute & 
      Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 
      Beijing 100021, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Cancer Res
JT  - Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
JID - 9315242
PMC - PMC5242450
OTO - NOTNLM
OT  - Anaplastic lymphoma kinase
OT  - crizotinib
OT  - fluorescence in situ hybridization
OT  - immunohistochemistry
OT  - lung adenocarcinoma
OT  - pleural effusion
EDAT- 2017/02/09 06:00
MHDA- 2017/02/09 06:01
PMCR- 2016/12/01
CRDT- 2017/02/09 06:00
PHST- 2017/02/09 06:00 [entrez]
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2017/02/09 06:01 [medline]
PHST- 2016/12/01 00:00 [pmc-release]
AID - cjcr-28-6-wangzheng [pii]
AID - 10.21147/j.issn.1000-9604.2016.06.07 [doi]
PST - ppublish
SO  - Chin J Cancer Res. 2016 Dec;28(6):606-616. doi: 
      10.21147/j.issn.1000-9604.2016.06.07.